A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL
Released On
January 31, 2023
Expires On
January 31, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology Oncology, Hospitalist, Pathology
Topic(s)
Leukemia, Lymphoma, Oncology
Scroll to the Bottom of this Information to Begin this Course
Sponsored by The University of Texas MD Anderson Cancer Center and The Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from Lilly.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other health care professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is designed for hematologists, oncologists and the multidisciplinary care team in both the academic and community hospital setting who care for/manage patients with CLL/SLL.
Program Overview
Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL/SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion from this visiting lecture series. This activity also includes downloadable slides from the series to improve care for your patients with CLL/SLL.
January 19, 2023: Zanubrutinib received FDA approval for CLL/SLL.
January 27, 2023: Pirtobrutinib received FDA approval for mantle cell lymphoma.
Learning Objectives
The University of Texas MD Anderson Cancer Center and ACHL present the latest in next generation BTK Inhibitors for CLL/SLL. Upon completion of this activity, clinicians will be able to:
- Discuss the limitations that are typically associated with currently available targeted agents used for the management of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
- Evaluate the most up-to-date clinical trial data surrounding emerging Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of CLL/SLL in the relapsed/refractory setting
- Apply recent evidence of emerging BTK inhibitors into the clinical context of current paradigms in the area of CLL/SLL
Faculty
Chair
Nitin Jain, MD
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Co-Chair
Jacqueline Barrientos, MD, MS
Chief, Hematologic Malignancies
Director, Oncology Research
Assistant Professor
Columbia University Division of Hematology/Oncology at Mount Sinai Medical Center
Adjunct Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell
Adjunct Associate Professor, Feinstein Institutes for Medical Research
Mount Sinai Medical Center
Miami Beach, FL
Faculty
Catherine Coombs, MD
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, CA
Sameer Parikh, MD, MBBS (Presenter)
Assistant Professor of Medicine
Department of Medicine, Division of Hematology
Mayo Clinic
Rochester, MN
Physician Continuing Education
Accreditation Statement
In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation
The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
Disclosures of Conflicts of Interest
The Accreditation Council for Continuing Medical Education has announced standards and guidelines to ensure that individuals participating in CME activities are aware of program chair(s), planning committee member, faculty/teacher/author, or CME activity reviewer relationships with an ineligible company that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all financial relationships with any ineligible company. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: pirtobrutinib and nemtabrutinib for CLL/SLL.
- Nitin Jain, MD*
-
- Consulting fee: AbbVie Inc., Adaptive Biosciences, AstraZeneca US, Beigene, Bristol-Myers Squibb Company, CareDx, Cellectis, Genentech, Inc., Ipsen US, Janssen Biotech, Inc., Pharmacyclics LLC, MEI Pharma, Precision Biosciences, Servier Pharmaceuticals, TG Therapeutics
- Honoraria: Janssen Biotech, Inc., MEI Pharma, Novartis Pharmaceutical Corporation, TG Therapeutics
- Jacqueline Barrientos, MD, MS*
-
- Advisor: AstraZeneca US, Beigene, MEI Pharma, Pharmacyclics LLC
- Grant or research support: Oncternal, Pharmacyclics LLC, Velosbio
- Catherine Callaghan Coombs, MD*
-
- Consulting fee: AbbVie Inc., AstraZeneca US, Beigene, Genentech, Inc., Lilly USA, LLC
- Honoraria: Janssen Biotech, Inc., MEI Pharma, MingSight, Novartis Pharmaceuticals Corporation, TG Therapeutics
- Membership on advisory committees or review panel: Octapharma
- Speakers bureau: AbbVie Inc., Genentech, Inc.
- Sameer Parikh, MD, MBBS*
-
- Advisor: AbbVIe Inc., Amgen Inc., AstraZeneca US, Janssen Biotech, Inc., Merck Sharp & Dohme Corp., Novalgen Limited, Pharmacyclics LLC, TG Therapeutics
- Grant or research support: AstraZeneca US, Genentech, Inc., Janssen Biotech, Inc., Merck Sharp & Dohme Corp.
Staff and Reviewer Disclosures
The University of Texas MD Anderson Cancer Center has, through a formal review process, mitigated all conflicts of interest prior to this activity. For information on this process, please contact the Department of Continuing Professional Education at (713) 792-5357.
Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below.
The following financial relationships have been provided:
- Nitin Jain, MD
-
- Consulting fee: AbbVie Inc., Adaptive Biosciences, AstraZeneca US, Beigene, Bristol-Myers Squibb Company, CareDx, Cellectis, Genentech, Inc., Ipsen US, Janssen Biotech, Inc., Pharmacyclics LLC, MEI Pharma, Precision Biosciences, Servier Pharmaceuticals, TG Therapeutics
- Honoraria: Janssen Biotech, Inc., MEI Pharma, Novartis Pharmaceuticals Corporation, TG Therapeutics
- Jacqueline Barrientos, MD, MS
-
- Advisor: AstraZeneca US, Beigene, MEI Pharma, Pharmacyclics LLC
- Grant or research support: Oncternal, Pharmacyclics LLC, Velosbio
Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers below have indicated NO financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity.
Aminah Abdullah
Emily Bennett
Katlyn Cooper
Michelle Forcier, MS
Danya Garner, PhD, MSN, RN
Tamara Greiner, MA, CHCP
Don Hallagan
Lisa Keckich
Ritesh Kothari
Natasha Mitchner, PhD
Laurie Novoryta
Anne Perch, MBA, CHCP
Vanessa Senatore
Margaret Sheils
CME Activity Reviewers/Approver
Samuel Kareff, MD, MPH
Instructions for Participation and Credit
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions about this activity, please contact Michelle Forcier at [email protected].
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
Disclosure of Unlabeled Use
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Disclaimer
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
For CME questions please contact: Michelle Forcier at [email protected].